LPTH

LightPath is a sub-scale specialty optics company whose financials do not justify a $596M market cap or 16x P/S multiple. FY2025 revenue of $37.2M grew 17% YoY, but the MD&A reveals the growth is almost entirely acquired — G5 Infrared contributed $1.6M in coatings and $4.0M in cameras/modules to the assemblies group, meaning organic growth across the legacy infrared and visible component lines was modest at best. Worse, the core Germanium-based infrared business lost a large annual contract due to supply-chain pricing/availability problems flagged in the Risk Factors (China's July 2023 Germanium export restrictions), and visible components continue to decline in commercial and medical channels with a $0.5M inventory reserve charge as evidence.

Profitability is moving the wrong direction. Net loss widened to -$14.9M (vs -$8.0M prior year, -85.7% YoY), operating margin deteriorated to -31.8%, and SG&A jumped 29% (+$3.5M) largely from G5 integration costs. Operating cash flow flipped to -$8.3M from roughly breakeven, while the company tapped long-term debt (up from ~$0.3M to $4.8M) and diluted shareholders by ~13%. With only $4.88M cash against $17.1M current liabilities and a -$231M accumulated deficit explicitly called out in Risk Factors as a going-concern-adjacent warning, the runway is thin. Equity dropped 48% YoY to $15.6M, pushing liabilities/equity to 2.0x.